CSIMarket Company Name, Ticker, Industry, else..
 
Trevi Therapeutics Inc   (TRVI)
Other Ticker:  
 
 
Price: $1.1100 $-0.02 -1.333%
Day's High: $1.15 Week Perf: 1.83 %
Day's Low: $ 1.10 30 Day Perf: -36.93 %
Volume (M): 404 52 Wk High: $ 3.50
Volume (M$): $ 449 52 Wk Avg: $2.20
Open: $1.11 52 Wk Low: $0.97



 Market Capitalization (Millions $) 110
 Shares Outstanding (Millions) 99
 Employees 30
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 0

Trevi Therapeutics Inc
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company that primarily focuses on developing and commercializing drugs for neurological disorders. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

The company's lead product candidate is nalbuphine ER, which is a novel extended-release formulation of nalbuphine, an opioid-based drug. It is under development for the treatment of several severe neurological conditions, including pruritus (severe itching) associated with conditions such as chronic liver disease and uremic (kidney-related) pruritus.

Trevi's pipeline also includes other drug candidates. One of them is TRV027, which is a novel human angiotensin type II receptor (AT2R) agonist. It is under development for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), which are severe and often fatal conditions that affect the lungs.

The company's scientific approach is based on in-depth understanding of the underlying pathophysiology of the diseases it targets. It uses innovative drug delivery technologies to extend the half-life of its drug candidates and optimize their therapeutic potential.

Trevi has partnerships with several leading institutions in the field of neurological research, including the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, and the Michael J. Fox Foundation for Parkinson's Research. The company is also engaged in collaborations with academic institutions and other pharmaceutical companies to advance the understanding of neurological diseases and develop innovative therapies.

In addition, Trevi has a strong management team with extensive experience in drug development and commercialization. Its executives have a track record of successfully bringing innovative therapies to market.

Overall, Trevi Therapeutics Inc. is a promising biopharmaceutical company that is dedicated to developing innovative therapies for severe neurological disorders. With its strong scientific approach, innovative drug delivery technologies, and experienced management team, it has the potential to create significant value for patients and investors alike.


   Company Address: 195 Church Street New Haven 6510 CT
   Company Phone Number: 304-2499   Stock Exchange / Ticker: NASDAQ TRVI
   TRVI is expected to report next financial results on March 15, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators



As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.
Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry



In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.
Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.
Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.
Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.





 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com